Last updated: February 22, 2026
What is the current status of NDC 31722-0404?
NDC 31722-0404 is a prescription drug marketed under the brand Ozempic (semaglutide). It is a GLP-1 receptor agonist used for managing type 2 diabetes and weight management. The drug has received FDA approval for both indications and has seen increasing adoption worldwide.
Market landscape overview
Sales volume and revenue
In 2022, Ozempic reported global sales exceeding $3.2 billion, driven primarily by use in type 2 diabetes and obesity. The drug’s market share among GLP-1 receptor agonists increased from 35% in 2020 to over 50% in 2022, owing to its efficacy and physician preference.
Competition
Key competitors include:
- Wegovy (semaglutide): indicated for weight management at higher doses. Sales reached approximately $1.0 billion in 2022.
- Trulicity (dulaglutide): 2022 sales around $4.6 billion.
- Victoza (liraglutide): 2022 sales roughly $2.6 billion.
NDC 31722-0404’s primary positioning is within the diabetes segment, but its growing use in obesity expands its market reach.
Market trends
- Increased adoption driven by new guidelines emphasizing GLP-1 receptor agonists.
- Rising obesity rates globally—estimated to reach 595 million adults by 2030—boosts demand.
- Patent exclusivity and recent label expansions contribute to revenue growth.
Price analysis
Current pricing
Wholesale acquisition cost (WAC) for NDC 31722-0404 is approximately $1,200 per 4-week carton (injectable pen). Actual transaction prices can vary with insurance, discounts, and pharmacy negotiations, generally ranging from $700 to $1,000 out-of-pocket.
Pricing compared to competitors
| Product |
Typical Monthly Cost |
Indications |
Dosing Schedule |
| Ozempic (NDC 31722-0404) |
$1,200 |
Diabetes, obesity (off-label) |
Weekly injection |
| Wegovy |
$1,350 |
Obesity |
Weekly injection |
| Trulicity |
$1,200 |
Diabetes |
Weekly injection |
| Victoza |
$1,250 |
Diabetes, off-label weight management |
Daily injection |
Ozempic pricing aligns with Trulicity and Wegovy but is slightly less costly in some pharmacies after discounts.
Price projection assumptions
- The global market will grow at a compound annual growth rate (CAGR) of approximately 12% through 2027.
- Increased competition and biosimilar development may exert downward pressure on prices.
- The drug’s approval for new indications, including pediatric use and combination therapies, will expand revenue.
Short-term (2023–2025)
- Wholesale prices are projected to remain stable, with minor fluctuations due to inflation and supply chain factors.
- Out-of-pocket costs may decline with pharmacy benefit manager (PBM) negotiations.
Mid-term (2025–2027)
- Prices may decline by 10–15% as biosimilars or generics enter some markets, depending on patent status.
- Strategic discounting may influence net prices for payers.
Long-term (2027 and beyond)
- Brand dominance may diminish with biosimilar entries.
- Prices are expected to decrease by 20–25%, with potential stabilization at new equilibrium levels driven by innovation and market penetration.
Patent and regulatory considerations
- The original patent for semaglutide expired in 2023 in some territories, opening pathways for biosimilar competition.
- Pending biosimilar filings expected to launch from 2024 onward.
- Regulatory pathways for biosimilars differ globally, impacting timing and pricing strategies.
Key factors influencing price trajectory
- Patent litigation outcomes.
- Biosimilar approval and market entry.
- Physician and patient acceptance.
- Payer reimbursement policies.
Summary of projections
| Year |
Wholesale Price Estimate |
Market Dynamics |
| 2023 |
$1,200–$1,350 |
Stable approvals, moderate price fluctuation |
| 2024 |
$1,150–$1,300 |
Biosimilar approvals, initial price competition |
| 2025 |
$1,100–$1,250 |
Increased biosimilar market share, price erosion |
| 2026 |
$900–$1,150 |
Biosimilar penetration, patent expirations influence prices |
| 2027 |
$900–$1,100 |
Market stabilization, competitive biosimilars |
Key Takeaways
- NDC 31722-0404 (Ozempic) remains a leading GLP-1 therapy, with stable prices in the near term.
- Pricing is influenced heavily by biosimilar development, patent status, and competitive dynamics.
- Growth driven by expanding indications and global diabetes and obesity trends.
- Prices likely to decline gradually over the next five years due to biosimilar competition and market saturation.
FAQs
1. What factors could accelerate price declines for Ozempic?
The entry of biosimilars, patent litigations favorable to generics, and shifts in payer reimbursement policies.
2. Will the price differential between Ozempic and Wegovy change?
Potentially, as dose-specific factors and market positioning evolve, but both likely remain within similar ranges in the near term.
3. How do insurance plans impact the out-of-pocket cost?
Negotiated discounts, copay assistance programs, and formulary placement significantly lower patient costs, sometimes below wholesale prices.
4. Are there geographic differences in pricing?
Yes, prices vary globally due to regulatory environments, market competition, and healthcare system differences.
5. How will emerging treatments influence Ozempic’s market share?
New GLP-1 formulations, dual agonists, and combination therapies may cannibalize sales if they demonstrate better efficacy, safety, or convenience.
References
- IQVIA. (2022). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration (FDA). (2022). Ozempic (semaglutide) prescribing information.
- EvaluatePharma. (2022). World Market for GLP-1 Receptor Agonists.
- Centers for Disease Control and Prevention (CDC). (2022). Adult Obesity Prevalence.
- Biosimilar Development & Regulation. (2023). Patent Expirations and Biosimilar Pathways.
